MTOR and prostate cancer: For those molecules that were demonstrated to be correlated with poor prognosis in HNC patients (Figure 4C), RHEB was also found overexpressed in prostate cancer, associated with poor prognosis [34], and promoted cell growth via the regulation of the mTOR signaling pathway [35,36].